Firms team up to develop cancer drugs in potential $540M deal

08/6/2013 | Reuters · Genetic Engineering & Biotechnology News

Bayer HealthCare and Compugen signed a preclinical research agreement centered on antibody-based cancer immunotherapies. Bayer will get the rights to further develop and market the drugs arising from the collaboration. The deal entitles Compugen to $10 million upfront and as much as $530 million in milestone fees plus sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC